Apyx Medical Corporation (APYX) |
| 3.88 -0.13 (-3.24%) 01-13 16:00 |
| Open: | 4.01 |
| High: | 4.06 |
| Low: | 3.72 |
| Volume: | 325,377 |
| Market Cap: | 148(M) |
| PE Ratio: | -10.78 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 4.83 |
| Resistance 1: | 4.14 |
| Pivot price: | 3.57 |
| Support 1: | 3.65 |
| Support 2: | 3.35 |
| 52w High: | 4.44 |
| 52w Low: | 0.755 |
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
| EPS | -0.360 |
| Book Value | 0.160 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.731 |
| Profit Margin (%) | -30.35 |
| Operating Margin (%) | -6.46 |
| Return on Assets (ttm) | -10.1 |
| Return on Equity (ttm) | -168.1 |
Tue, 13 Jan 2026
Apyx Medical Stock Strengthens On AYON Launch And U.S. Aesthetics Demand - RTTNews
Mon, 12 Jan 2026
Apyx Medical reports 34% revenue growth in Q4 2025 By Investing.com - Investing.com Nigeria
Mon, 12 Jan 2026
Apyx Medical Corporation reports preliminary, unaudited, fourth quarter and full year 2025 revenue results - marketscreener.com
Mon, 12 Jan 2026
Apyx Medical reports preliminary Q4 revenue $19M-$19.2M, consensus $17.47M - TipRanks
Mon, 12 Jan 2026
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results - GlobeNewswire
Tue, 16 Dec 2025
Roth Capital Initiates Coverage of Apyx Medical (APYX) with Buy Recommendation - Nasdaq
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |